# Problem Statement: Problem P2

## Drug Safety Signal Detector & Regulatory Submission Readiness Checker
**IBM Bobathon 2026** — Life Sciences & Healthcare Track

---

## 1. Industry Context & Operational Bottlenecks

In the life sciences and biopharmaceutical industry, bringing safe and effective therapies to market and ensuring ongoing patient safety requires continuous oversight across two critical phases of the product lifecycle:

1. **Post-Marketing Surveillance & Pharmacovigilance (PV)**: Continuous monitoring of spontaneous adverse event reporting databases (such as the US FDA FAERS database with over 20 million historical reports) to detect subtle, emerging safety signals before widespread harm occurs.
2. **Pre-Marketing Regulatory Submission & Dossier Compilation**: Ensuring that multi-volume Common Technical Document (CTD) dossiers conform strictly to International Council for Harmonisation (ICH) M4 guidelines across Modules 1 through 5 prior to statutory health authority filing.

Currently, these operations are severely constrained by fragmented tooling, high data volumes, manual checklist reviews, and disconnected operational silos.

---

## 2. Target Users & Stakeholders

- **Pharmacovigilance (PV) Scientists & Epidemiologists**: Responsible for triaging adverse event reports, calculating disproportionality statistics, and identifying emerging safety signals across large-scale spontaneous reporting databases.
- **Regulatory Affairs Specialists & Submission Managers**: Responsible for assembling, auditing, and verifying CTD dossiers (Modules 1–5) to prevent Refusal-to-File (RTF) actions by health authorities (FDA, EMA, PMDA).
- **Medical Safety Reviewers & Risk Management Leads**: Responsible for evaluating the clinical causality behind statistical alerts and authoring Risk Evaluation and Mitigation Strategies (REMS).
- **Cross-Functional Life Sciences Leadership**: Executive directors needing real-time visibility into filing health, audit readiness, and emerging portfolio safety liabilities.

---

## 3. The Pharmacovigilance Challenge (Mode 1)

### Massive Data Volume & Velocity
The FDA Adverse Event Reporting System (FAERS) ingests hundreds of thousands of spontaneous adverse event reports each quarter. Safety evaluators face the classic "needle in a haystack" dilemma, where true drug-induced adverse reactions are obscured within millions of confounding reports.

### The Cost of Delayed Signal Detection: The Vioxx Benchmark
The historical tragedy of **Vioxx (Rofecoxib)** highlights the critical need for proactive mathematical surveillance:
- An estimated **27,000+ excess cardiovascular events and myocardial infarctions** occurred before the drug was voluntarily withdrawn from global markets on September 30, 2004.
- Mathematical disproportionality analysis (Proportional Reporting Ratio, $\text{PRR} \ge 2.0$) revealed significant statistical signals as early as **January 31, 2004** — offering **242 days (~8 months) of early detection lead time** that could have prompted earlier regulatory intervention.

### Limitations of Manual Triage
Traditional manual review workflows fail because:
- Disproportionality cannot be identified by simple raw case counts alone; it requires computing background population ratios across immense drug-event contingency tables.
- Statistical metrics (PRR, Pearson Chi-Square, 95% log-normal confidence intervals) are computationally demanding and lack contextual clinical explanations when presented as raw tables.

---

## 4. The Regulatory Submission Readiness Challenge (Mode 2)

### Complex ICH M4 Architecture
The Common Technical Document (CTD) format is organized into five complex, interdependent modules spanning over 100,000 pages of clinical, nonclinical, and quality documentation:
- **Module 1**: Regional Administrative Information and Prescribing Information
- **Module 2**: CTD Summaries (Clinical Overview, Nonclinical Overview, Quality Overall Summary)
- **Module 3**: Quality (Chemistry, Manufacturing, and Controls - CMC)
- **Module 4**: Nonclinical Study Reports
- **Module 5**: Clinical Study Reports & Tabulations

### The Risk of Refusal-to-File (RTF) Delays
Health authorities enforce strict structural completeness. If a candidate dossier omits a mandatory section (such as Module 2.4 Nonclinical Overview or Module 5.3.5.1 Clinical Efficacy Reports):
- Regulators issue immediate **Refusal-to-File (RTF)** decisions or extensive Information Requests (IRs).
- Submission delays cost biopharma sponsors an estimated **$1M–$2M per day** in lost market exclusivity and delayed patient access.

### The Audit Bottleneck
Regulatory affairs teams currently audit dossier readiness using manual spreadsheets across thousands of line items, creating high-risk human errors under extreme deadline pressures.

---

## 5. Scope of the PharmSignals Solution

PharmSignals directly solves both challenges in a unified, production-grade intelligence platform:

1. **Automated Disproportionality Engine**: Vectorized computation of Evans PRR and Pearson $\chi^2$ on real openFDA FAERS datasets, complete with an interactive Adverse Event Bubble Chart and custom 2×2 contingency calculator.
2. **Digital-Twin Historical Backtesting**: Reconstructs monthly walk-forward trajectories across historical benchmarks (Vioxx, Avandia, Baycol) to prove early signal emergence lead times.
3. **ICH M4 CTD Readiness Checker**: Ingests candidate dossier outlines (text, JSON, PDF), scores completeness per module, and generates prioritized regulatory gap matrices with official ICH citations.
4. **IBM Bob AI Copilot**: Provides grounded, explainable natural-language assistance across safety and regulatory operations with zero hallucinations.
